Entity

Time filter

Source Type

Covington, LA, United States

Trademark
TCA Cellular Therapy LLC | Date: 2008-02-06

Pharmaceutical preparations for the treatment of heart/vascular disease.


Allers C.,TCA Cellular Therapy LLC | Jones J.A.,TCA Cellular Therapy LLC | Jones J.A.,Southeastern Louisiana University | Lasala G.P.,TCA Cellular Therapy LLC | Minguell J.J.,TCA Cellular Therapy LLC
Regenerative Medicine | Year: 2014

Based on the distinctive cellular, molecular and immunomodulatory traits of mesenchymal stem cells (MSC), it has been postulated that these cells may play a critical role in regenerative medicine. In addition to the participation of MSC in the repair of mesodermal-derived tissues (bone, cartilage), robust data have suggested that MSC may also play a reparative role in conditions involving damage of cells of ectodermal origin. The above content has been supported by the capability of MSC to differentiate into neuron-like cells as well as by a competence to generate a 'neuroprotective' environment. In turn, several preclinical studies have put forward the concept that MSC therapy may represent an option for the treatment of several neurological disorders and injuries, including amyotrophic lateral sclerosis. We expect that the above foundations, which have inspired this review, may result in the founding of an effective and/or palliative therapy for amyotrophic lateral sclerosis. © 2014 Future Medicine Ltd. Source


Lasala G.P.,TCA Cellular Therapy LLC | Silva J.A.,TCA Cellular Therapy LLC | Gardner P.A.,Venous and Arterial Surgery Clinic | Minguell J.J.,TCA Cellular Therapy LLC
Angiology | Year: 2010

The infusion of a source of endothelial progenitors (EPCs) to limb ischemia (LB) patients has been used to increase angiogenesis. Because the formation of new blood vessels involves, in addition to EPCs, other cells and angiogenic regulators, we postulate that a combination cell therapy including EPCs and mesenchymal stem cells (a source of pericytes progenitors and angiogenic regulators) may represent a preferential stimuli for the development of blood vessels. In this phase I clinical trial, patients with LI were infused with a cell product consisting of autologous bone marrow-derived mononuclear and mesenchymal stem cells. After 10 2 months of follow-up, efficacy assessment demonstrated improvements in walking time, ankle brachial pressure, and quality of life. Concomitantly, angiographic and 99mTc-TF perfusion scintigraphy scores confirmed increased perfusion in the treated limbs. These results show that the use of a combination cell therapy is safe, feasible, and appears effective in patients with LI. © 2010 The Author(s). Source


Lasala G.P.,TCA Cellular Therapy LLC | Silva J.A.,TCA Cellular Therapy LLC | Minguell J.J.,TCA Cellular Therapy LLC
Journal of Thoracic and Cardiovascular Surgery | Year: 2012

Objective: Angiogenesis involves the interplay of endothelial progenitor cells, pericytes, growth factors, and cellular matrix components. The use of mesenchymal stem cells, which are closely related to pericytes and produce diverse angiogenic growth factors and matrix molecules, seems to be a promising therapeutic modality. We postulate that the use of a combination cell product (mesenchymal stem cells in conjunction with a source of endothelial progenitor cells) is safe and efficient and may optimize the clinical results obtained with the use of endothelial progenitor cells alone. This study assessed whether the intramuscular infusion of a combination cell product represents a viable, effective, and lasting therapeutic modality to improve perfusion in severely ischemic limbs. Methods: Patients with limb ischemia (n = 26) received an intramuscular (gastrocnemius) infusion of the combination cell product in the most ischemic leg and a placebo product in the (less ischemic) contralateral leg. Clinical follow-up (months 0.5, 1, 2, and 4 postinfusion) included evaluation of pain-free walking time, ankle-brachial index, perfusion scintigraphy, and quality of life survey. Results: No adverse events occurred after infusion. Efficacy assessment indicated that after cell infusion there was a significant improvement in walking time and ankle-brachial index. In addition, technetium-99m-tetrofosmin scintigraphy demonstrated a significant increase of perfusion in the treated limbs compared with the respective control legs. Conclusions: This phase II clinical trial shows that the use of a combination cell therapy is safe and effective in increasing blood flow in the ischemic legs of patients with limb ischemia. © 2012 by The American Association for Thoracic Surgery. Source

Discover hidden collaborations